News
Roche’s Tecentriq/Avastin combo improves survival in liver cancer
Roche is planning to present updated data confirming that its immunotherapy combination, consisting of Tecentriq (atezolizumab) and Avastin (bevacizumab), improves overall survival (OS) in patients with a type of liver cancer.